Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Ani Balmanoukian

Ani Balmanoukian

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Edward B. Garon, M.D., Naiyer A. Rizvi, M.D., Rina Hui, M.B., B.S., Natasha Leighl, M.D., Ani S. Balmanoukian, M.D., Joseph Paul Eder, M.D., Amita Patnaik, M.D., Charu Aggarwal, M.D., Matthew Gubens, M.D., Leora Horn, M.D., Enric Carcereny, M.D., Myung-Ju Ahn, M.D., Enriqueta Felip, M.D., Jong-Seok Lee, M.D., Matthew D. Hellmann, M.D., Omid Hamid, M.D., Jonathan W. Goldman, M.D., Jean-Charles Soria, M.D., Marisa Dolled-Filhart, Ph.D., Ruth Z. Rutledge, M.B.A., Jin Zhang, Ph.D., Jared K. Lunceford, Ph.D., Reshma Rangwala, M.D., Gregory M. Lubiniecki, M.D., Charlotte Roach, B.S., Kenneth Emancipator, M.D.,
and Leena Gandhi, M.D.

N Engl J Med 2015;372:2018-28.
DOI: 10.1056/NEJMoa1501824
Copyright © 2015 Massachusetts Medical Society

More publications from Ani Balmanoukian

2021-11-06T07:32:45+01:00November 6, 2021|Other article for therapists|

Share This Story, Choose Your Platform!

Go to Top